TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36339775
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 40 mg·kg‐1 + 10 mg·kg‐1·h‐1
Study: 36339775
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at an initial dose of 0.2 μg·kg‐1·min‐1
Study: 34819273
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg (subcutaneous) at week 0, week 4, then every 8 weeks through week 44
Study: 36428216
Drug: IV melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV melatonin at a daily dose of 60 mg, administered continuously for over 30 minutes starting on the day of diagnosis during a 5-day period.
Study: 35641993
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX-A) injection in the lateral pterygoid muscle
Study: 35352277
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 µg as a rapid intravenous bolus
Study: 35352277
Drug: Carbetocin 100
Normalized name: Carbetocin 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 100 µg over 10 min infusion
Study: 35352277
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prophylactic phenylephrine infusion)
Study: 32053567
Drug: Group Integrated
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Integrated Neurocognitive Therapy (INT)
Study: 34184536
Drug: Site-specific labeling
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-specific labeling of IgG antibodies using a two-step protocol with microbial transglutaminase.
Study: 34184536
Drug: DNA-PAINT for
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNA-PAINT for labeling IgG antibodies.
Study: 32932174
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg elemental zinc supplement
Study: 32416145
Drug: E2 75
Normalized name: Estradiol 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 75 mcg/day
Study: 32416145
Drug: E2 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 100 mcg/day
Study: 32416145
Drug: E2 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 200 mcg/day
Study: 33470769
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol (tE2, n = 21)
Study: 33470769
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (n = 19)
Study: 35508300
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine nursing intervention of burying seeds at auricular points (Control)
Study: 36322258
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (daily, weekly, or monthly)
Study: 36322258
Drug: Weekly cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cholecalciferol supplementation
Study: 35618446
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein shot (15 g of protein)
Study: 33486770
Drug: 3 mg/ml
Normalized name: RNA 0.63 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/ml oligomer chitosan solution
Study: 33486770
Drug: 6 mg/ml
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/ml oligomer chitosan solution
Study: 33486770
Drug: 3 mg/ml
Normalized name: RNA 0.63 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/ml 30 kDa chitosan solution
Study: 33486770
Drug: 6 mg/ml
Normalized name: phenol 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/ml 30 kDa chitosan solution
Study: 33486770
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet (Polident)
Study: 32013621
Drug: Experimental Occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Occupational Therapy (EOT)
Study: 33948951
Drug: Novel scaffold
Normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel scaffold treatment (n = 5)
Study: 32173950
Drug: Treatment Adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Adherence Programme (TAP)
Study: 34448111
Drug: Attachment and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment and Biobehavioral Catch-up (ABC) intervention (10 sessions) provided as a supplement to Early Head Start (EHS)
Study: 34703055
Drug: Modified pectoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified pectoral nerve block (30 ml of ropivacaine 0.2%)
Study: 36137599
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical management (BMM) combined with endovascular therapy
Study: 35805627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IF and SIT
Study: 33186740
Drug: Taselisib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib (4 mg) plus fulvestrant (500 mg)
Study: 36370124
Drug: Citalopram (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (add-on treatment)
Study: 33972742
Drug: tepotinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: tepotinib (500 mg once daily)
Study: 34003685
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug regimen change
Study: 35379575
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 g azithromycin orally on admission plus a third-generation cephalosporin intravenously for the first 48 hours, followed by amoxicillin 500 mg orally for another five days.
Study: 32650729
Drug: Metronidazole followed
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole followed by a commercial oral/vaginal probiotic
Study: 34673771
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) titrated based on weekly assessments, mean end-dose of 1.0 mg/kg/day
Study: 34673771
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) titrated based on weekly assessments
Study: 35769160
Drug: High-dose Bojungikgi-Tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Bojungikgi-Tang (BJIGT)
Study: 35769160
Drug: Standard-dose Bojungikgi-Tang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Bojungikgi-Tang (BJIGT)
Study: 35654863
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy + home exercise
Study: 35654863
Drug: Paraffin therapy
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin therapy + home exercise
Study: 33984886
Drug: Levodopa‐carbidopa intestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa‐carbidopa intestinal gel (LCIG) treatment
Study: 36045304
Drug: TLPLDC + G
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLPLDC + G
Study: 34936271
Drug: Tongyuan acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongyuan acupuncture combined with medication
Study: 34936271
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (estradiol valerate tablets, 2 mg per day from the fifth day of menstruation)
Study: 36194181
Drug: AB-506 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-506 at 160 mg daily for 28 days
Study: 36194181
Drug: AB-506 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-506 at 400 mg daily for 28 days
Study: 36194181
Drug: AB-506 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-506 at 400 mg daily for 28 days in Asian HS
Study: 32898838
Drug: Lactoferrin, ethanol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin, ethanol, hydroxychloroquine, quaternary ammonium compounds
Study: 32898838
Drug: Quaternary ammonium
Normalized name: Quaternary ammonium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quaternary ammonium compounds, hydroxychloroquine
Study: 32898838
Drug: Quaternary ammonium
Normalized name: Quaternary ammonium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quaternary ammonium compounds, alcohol-based nasal antiseptics
Study: 33162314
Drug: Back massage
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back massage (15 minutes daily for four days)
Study: 32893505
Drug: Increased loop
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased loop diuretic dose
Study: 32893505
Drug: Combination diuretic
Normalized name: atenolol and other diuretics, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diuretic therapy (loop diuretic plus chlorothiazide)
Study: 32893505
Drug: Standard loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard loop diuretic therapy
Study: 34593120
Drug: Initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial triple therapy (macitentan, tadalafil, and selexipag)
Study: 34593120
Drug: Initial double
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial double therapy (macitentan, tadalafil, and placebo)
Study: 34273682
Drug: Juçara fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juçara fruit juice (JFJ) 250 mL
Study: 32041605
Drug: Biological with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological with best practice prevention (B+P)
Study: 32248829
Drug: Tocilizumab (subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (subcutaneously at 162 mg/week)
Study: 32248829
Drug: Prednisone (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (orally at 10 mg/day)
Study: 35193718
Drug: Brazil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil and cashew nuts group (BN-Group): Energy-restricted diet containing daily 45 g of nuts (15 g of Brazil nuts + 30 g of cashew nuts), n=21
Study: 33052965
Drug: MDMA-assisted psychotherapy
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted psychotherapy (MAP) consisting of 2.5 trauma-focused psychotherapy sessions and two 8-hour sessions with MDMA (mean dose of 125 mg) followed by 3.5 integration sessions
Study: 33052965
Drug: Inactive placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo or 25–40 mg of MDMA
Study: 35166212
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point therapy (TriT)
Study: 35166212
Drug: Acupoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint therapy (AcuT)
Study: 34677153
Drug: Ozone group
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone group (received lung disinfection technique with ozone and standard COVID-19 treatment)
Study: 34677153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with ozone, only received standard COVID-19 treatment)
Study: 32464266
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (C‐PDT)
Study: 34838460
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Study: 34838460
Drug: Cetuximab combined
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab combined with modified FOLFOX6 (mFOLFOX6) or FOLFIRI chemotherapy
Study: 33864735
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 μg per actuation, total dose of 1600 μg, two puffs twice per day)
Study: 33710277
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg CBD and 5.4 mg THC daily
Study: 33710277
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg CBD and 10.8 mg THC daily
Study: 33710277
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg CBD and 16.2 mg THC daily
Study: 33710277
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg CBD and 21.6 mg THC daily
Study: 34329455
Drug: Alfentanil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil + Pregabalin (300 mg orally)
Study: 35760666
Drug: Auto-cross-linked hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-cross-linked hyaluronic acid gel
Study: 33990144
Drug: Fremanezumab (monthly)
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab (monthly)
Study: 32314464
Drug: Tofogliflozin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofogliflozin (20 mg/day)
Study: 32314464
Drug: Glimepiride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.5 mg/day)
Study: 36445874
Drug: High flavonoid
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavonoid pre-workout beverage (490 mg)
Study: 36445874
Drug: Low flavonoid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavonoid pre-workout beverage (5 mg)
Study: 34980546
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg), Vitamin D3 (400 IU), Collagen Peptides (5 g)
Study: 34980546
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg), Vitamin D3 (400 IU)
Study: 35231887
Drug: Placebo (aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (aluminum hydroxide suspension, 2.5 ml daily)
Study: 33704919
Drug: Probenecid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (500 mg every 6 hours)
Study: 32589828
Drug: SAMe (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe (200 mg) plus Lactobacillus plantarum HEAL9 (1 × 10⁹ CFU)
Study: 36270095
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg once daily for five days)
Study: 33135866
Drug: Probiotic-supplemented arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-supplemented arm (two 4 oz. servings of the probiotic yogurt product daily)
Study: 33064621
Drug: Music-based approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-based approach to teach pursed-lip breathing; patients meet twice weekly for eight weeks for melodica instruction, group music-making, and COPD education.
Study: 33542047
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days)
Study: 33453076
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation during pregnancy
Study: 36047511
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate 0.03 g per kg body weight per day
Study: 36047511
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate 0.06 g per kg body weight per day
Study: 36047511
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg day‐1 for 60 days (positive control)
Study: 32078063
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine concentration (UIC) < 100 μg/L
Study: 32078063
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine concentration (UIC) 100-199 μg/L
Study: 32078063
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine concentration (UIC) 200-299 μg/L
Study: 32078063
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine concentration (UIC) ≥ 300 μg/L
Study: 38689310
Drug: Intermittent IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent IV paracetamol
Study: 35023349
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level transcutaneous vagus nerve stimulation (tragus), 20 Hz, 1 mA below discomfort threshold, for 1 hour daily for 3 months.
Study: 35023349
Drug: Sham low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham low-level transcutaneous vagus nerve stimulation (earlobe), 20 Hz, 1 mA below discomfort threshold, for 1 hour daily for 3 months.
Study: 32080686
Drug: Traditional injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional injection (control)
Study: 616880400
Drug: ABP-700 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABP-700 (0.25 mg/kg and 0.35 mg/kg)
Study: 616880400
Drug: ABP-700 (1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABP-700 (1.00 mg/kg)
Study: 32356207
Drug: Daily preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily preventive zinc dispersible tablet (7 mg/d; PZ)
Study: 32356207
Drug: Daily micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micronutrient powder (10 mg zinc/d; MNP)
Study: 32356207
Drug: Therapeutic zinc
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic zinc supplements for diarrhea treatment (20 mg/d for 10 days; TZ)
Study: 32356207
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo powder (Control)
Study: 36293916
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (CC, no warm-up)
Study: 32487035
Drug: Ipilimumab in
Normalized name: ipilimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab in combination with nivolumab and trastuzumab
Study: 32487035
Drug: FOLFOX in
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX in combination with nivolumab and trastuzumab
Study: 32487035
Drug: Blood-based signatures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-based signatures (e.g. immune response or suppression of anti-HER2 resistance)
Study: 32470434
Drug: Bortezomib–lenalidomide–dexamethasone consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib–lenalidomide–dexamethasone consolidation therapy
Study: 33593836
Drug: Anti-pseudomonal antibiotics
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-pseudomonal antibiotics
Study: 32276603
Drug: SEIQoL-PF/G
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEIQoL-PF/G
Study: 36058429
Drug: Belimumab 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab 10mg/kg plus standard therapy (oral glucocorticoids and either cyclophosphamide or mycophenolate mofetil)
Study: 36058429
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard therapy (oral glucocorticoids and either cyclophosphamide or mycophenolate mofetil)
Study: 34110925
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiation therapy (IFRT) in Sonic Hedgehog MB patients
Study: 34110925
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal irradiation (LDCSI) in group 4 MB patients
Study: 32275771
Drug: Rifampicin 10
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 10 mg/day (weak induction)
Study: 32275771
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg/day (strong induction)
Study: 32604939
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy sessions based on connective tissue massage
Study: 32604939
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (ultrasound sessions without conductive gel and machine turned off)
Study: 33558661
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supervised impact loading and resistance exercise (ImpRes)
Study: 34129271
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a week range of motion (ROM) exercise over a 4 weeks period
Study: 36400737
Drug: Caring Connections
Normalized name: CONNECTING TUBE #M001229101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caring Connections (CC) intervention, a peer-based, recurrent letter writing programme designed to provide moments of positivity.
Study: 36400737
Drug: Caring Connections
Normalized name: CONNECTING TUBE #M001229101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caring Connections (CC) intervention
Study: 34557931
Drug: Ranger Drug‐Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranger Drug‐Coated Balloon (DCB)
Study: 33731199
Drug: Kanglaite injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanglaite injections (KLTi) 200 ml per day for 14 days